Clinical Trial Update: Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating anakinra to reduce CAR-T–related toxicity in patients with relapsed or refractory diffuse large B-cell lymphoma has completed, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma Transformed to Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• KINERET (ANAKINRA)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2025-01-28